Mitochondria and nuclei dual-targeted heterogeneous hydroxyapatite nanoparticles for enhancing therapeutic efficacy of doxorubicin
Source abstract
Abstract
Dual-targeted nanoparticles have been increasingly used to realize greater anti-proliferation effect by attacking double key sites of tumor cells. In order to retain nuclei inhibition effect and enhance DOX-induced apoptosis by mitochondrial pathway simultaneously, hyaluronic acid (HA) modified hydroxyapatite (HAP) nanoparticles (HAP-HA), the functional calcium-based tumor targeting nanoparticles, have been developed. In this nanosystem, HA acts as an active tumor-targeting ligand to bind the CD44 receptors which are overexpressed on the surface of tumor cells while HAP can load and deliver DOX to both nuclei and mitochondria of tumor cells. In this study, DOX-loaded HAP-HA nanoparticles (DOX/HAP-HA) exhibited satisfactory drug loading efficiency which was up to 214.55 ± 51.05 μg mg(-1) and showed a uniform nano-scaled particle size. The mitochondrial and nuclei targetability of DOX/HAP-HA was confirmed by confocal laser scanning microscopy analyses. Besides, western blot assay demonstrated that DOX/HAP-HA could markedly enhance mitochondrial cytochrome C leakage and thereby activate apoptotic cascade associated with it. In addition, in vivo anti-tumor efficacy and toxicity evaluation of DOX/HAP-HA indicated that DOX/HAP-HA was more effective and less harmful compared to other groups. DOX/HAP-HA might be a new promising targeted delivery system for effective cancer therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Proteoglycans and glycosaminoglycans research · Nanoparticle-Based Drug Delivery · Caveolin-1 and cellular processes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Mitochondria: an intriguing target for killing tumour-initiating cells10.1016/j.mito.2015.12.007 ↗
2. Targeted delivery to the nucleus10.1016/j.addr.2007.06.010 ↗
3. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian Cancer Institute experience
4. The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells
5. Survival and cell kinetics effects of adriamycin on mammalian cells
6. Doxorubicin, DNA torsion, and chromatin dynamics10.1016/j.bbcan.2013.12.002 ↗
7. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings10.1016/S0009-8981(03)00013-5 ↗
8. Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer10.1016/j.bcp.2014.04.001 ↗
9. New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients10.1016/j.fct.2010.04.007 ↗
10. Targeting mitochondria10.1021/ar700135m ↗
11. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells10.1016/j.biomaterials.2013.10.049 ↗
12. cRGD-functionalized, DOX-conjugated, and 64 Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging10.1016/j.biomaterials.2011.02.006 ↗
13. Subcellular effects of adriamycin in the heart: a concise review10.1016/S0022-2828(87)80392-9 ↗
14. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats10.1002/jat.889 ↗
15. Effect of coenzyme-Q10 on doxorubicin-induced nephrotoxicity in rats
16. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis10.1681/ASN.2007101109 ↗
17. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease10.1038/ki.1986.28 ↗
18. Podocyte injury and overexpression of vascular endothelial growth factor and transforming growth factor-beta 1 in adriamycin-induced nephropathy in rats10.1016/j.cyto.2012.04.014 ↗
19. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems10.1111/j.2042-7158.2012.01567.x ↗
20. Taurine zinc solid dispersions attenuate doxorubicin-induced hepatotoxicity and cardiotoxicity in rats10.1016/j.taap.2015.08.017 ↗
21. In vitro mineralization of silicon containing calcium phosphate bioceramics10.1111/j.1551-2916.2006.01368.x ↗
22. Doxorubicin-intercalated nano-hydroxyapatite drug-delivery system for liver cancer: an animal model10.1016/j.ceramint.2013.05.074 ↗
23. Biomimetic hydroxyapatite–drug nanocrystals as potential bone substitutes with antitumor drug delivery properties10.1002/adfm.200600361 ↗
24. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells10.1016/j.jconrel.2010.07.108 ↗
25. Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells10.3748/wjg.v9.i9.1968 ↗
26. Effect of hydroxyapatite nanoparticles on the ultrastructure and function of hepatocellular carcinoma cells in vitro10.1088/1748-6041/1/1/006 ↗
27. Effects of nano HAP on biological and structural properties of glass bone cement10.1002/jbm.a.30322 ↗
28. Preparation of nano-hydroxyapatite particles with different morphology and their response to highly malignant melanoma cells in vitro10.1016/j.apsusc.2008.06.114 ↗
29. Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells10.1016/j.biomaterials.2009.09.088 ↗
30. Effect of nano-and micro-hydroxyapatite/chitosan-gelatin network film on human gastric cancer cells10.1016/j.matlet.2008.02.072 ↗
31. Mitochondria-dependent apoptosis induced by nanoscale hydroxyapatite in human gastric cancer SGC-7901 cells10.1248/bpb.30.128 ↗
32. Oxidative stress and apoptosis induced by hydroxyapatite nanoparticles in C6 cells10.1002/jbm.a.33270 ↗
33. Incorporation of different antibiotics into carbonated hydroxyapatite coatings on titanium implants, release and antibiotic efficacy10.1016/j.jconrel.2004.06.011 ↗
34. Incorporation of tobramycin into biomimetic hydroxyapatite coating on titanium10.1016/S0142-9612(02)00157-6 ↗
35. Hyaluronan: from extracellular glue to pericellular cue10.1038/nrc1391 ↗
36. Polysaccharide-based nucleic acid nanoformulations10.1016/j.addr.2013.05.002 ↗
37. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?10.1038/nrc3023 ↗
38. Nanostructured hyaluronic acid-based materials for active delivery to cancer10.1517/17425241003730399 ↗
39. Hyaluronan-decorated polymer nanoparticles targeting the CD44 receptor for the combined photo/chemo-therapy of cancer10.1039/C4NR06910B ↗
40. The surface modification of hydroxyapatite nanoparticles by the ring opening polymerization of γ-benzyl-L-glutamate N -carboxyanhydride10.1002/mabi.200800324 ↗
41. Co-administration of the flavanol (-)-epicatechin with doxycycline synergistically reduces infarct size in a model of ischemia reperfusion injury by inhibition of mitochondrial swelling10.1016/j.ejphar.2014.09.042 ↗
42. Low molecular weight heparin-all-trans-retinoid acid conjugate as a drug carrier for combination cancer chemotherapy of paclitaxel and all-trans-retinoid acid10.1016/j.carbpol.2011.06.008 ↗
43. Cytochrome c as an experimental model protein10.1039/c0mt00089b ↗
44. Tumor delivery of macromolecular drugs based on the EPR effect10.1016/j.addr.2010.03.011 ↗
45. Stabilization of the T1 fragment of glycophorin AN through interactions with N-and O-linked glycans10.1038/nsb0396-228 ↗
46. Exercise training decreases rat heart mitochondria free radical generation but does not prevent Ca2+-induced dysfunction10.1152/japplphysiol.00849.2006 ↗
47. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows10.1016/j.jbiomech.2008.03.021 ↗
48. Intravascular delivery of particulate systems: does geometry really matter?10.1007/s11095-008-9697-x ↗
49. The tumor microenvironment10.1016/j.suronc.2011.09.001 ↗
50. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates10.1016/j.addr.2011.09.006 ↗
51. Acetals as pH-sensitive linkages for drug delivery10.1021/bc049853x ↗
52. A novel graphene nanodots inlaid porous gold electrode for electrochemically controlled drug release10.1016/j.talanta.2015.09.020 ↗
53. Long-term doxorubicin release from multiple stimuli-responsive hydrogels based on α-amino-acid residues10.1016/j.ejpb.2014.06.005 ↗
54. pH-tunable calcium phosphate covered mesoporous silica nanocontainers for intracellular controlled release of guest drugs10.1002/anie.201101536 ↗
55. The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles10.1016/j.biomaterials.2012.04.057 ↗
56. Combination chemotherapy of doxorubicin, all-trans retinoic acid and low molecular weight heparin based on self-assembled multi-functional polymeric nanoparticles10.1088/0957-4484/26/14/145101 ↗
57. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly (γ-benzyl l-glutamate)-b-hyaluronan polymersomes10.1016/j.biomaterials.2009.12.043 ↗
58. Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria10.1038/sj.cdd.4400946 ↗
59. The antioxidant and anti-inflammatory efficiency of hyaluronic acid after third molar extraction10.1016/j.jcms.2015.04.022 ↗
60. Ivanov · 2007 · 137
61. Membrane cholesterol contents influence the protective effects of quercetin and rutin in erythrocytes damaged by oxidative stress10.1016/j.cbi.2006.03.004 ↗
62. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity10.1016/j.tox.2005.10.015 ↗
63. Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on adriamycin-induced toxicity of human renal tubular epithelial cell (HK-2)10.1016/j.ejphar.2012.03.001 ↗
64. Mitochondria and calpains mediate caspase-dependent apoptosis induced by doxycycline in HeLa cells10.1007/s00018-005-5565-6 ↗